We have re-analyzed previously published gene expression data from ninety-four pancreatic ductal adenocarcinomas (PDAC) samples. We determined the gene expression profile of genes differentially expressed in PDAC compared to non-malignant pancreatic tissue. Using the 100 top-ranked genes, we were able to discriminate between PDAC and non-malignant pancreatic tissue. A hierarchical cluster analysis revealed only a 6 % false discovery rate. The prognostic strength of these discriminative genes was underscored by a SVM classification and 3-fold cross validation with an 89 % correct class assignment. The annotation of the 100 top-ranked genes revealed that most of the genes were involved in the processes of signal transduction, cell adhesion, extracellular matrix organization and cell migration. The most greatly affected signal cascade was the transforming growth factor receptor signaling pathway, which was significantly enriched in the top-ranked genes. Furthermore, we identified eleven genes that were associated with good prognosis.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive malignancy and one of the most lethal types of human cancer [1] [2] [3] . PDAC in Germany shows an increased incidence, with 15.630 cases in 2009 to 16 .080 in 2010, and up to an estimated 17.400 cases in 2014. The number of deaths in 2010 by this disease is, with 15.487 cases, almost as high as the incidence. The 5-year survival rate of PDAC in Germany is 7% [1] . Tumor resection is today the best therapeutic option and the only therapy to achieve long-term survival. However, most patients were diagnosed in an advanced stage of the disease, namely metastatic (50%) or locally advanced cancer (30%) [4] , where standard therapy is limited to conventional chemotherapy, at least in the case of metastatic PDAC. Standard therapy has been and continues to be a systemic chemotherapy with gemcitabine [5] . In the last years, it has been shown that three therapies, namely gemcitabine-erlotinib, FOLFIRINOX, and gemcitabinenab-paclitaxel, prolonged overall survival (OS) in PDAC patients, when compared with gemcitabine monotherapy [6] . Although the survival benefit for the combination of the EGFR tyrosine-kinase-inhibitor erlotinib and gemcitabine was significant compared to gemcitabine monotherapy, this regime leads only to an *Address correspondence to this author at the Charité Medical University Berlin, Institute of Biochemistry, Charitéplatz 1 / Sitz: Virchowweg 6, 10117 Berlin, Germany; Tel: +49 30 450 528087; Fax: +49 30 450 52945; E-mail: andreas.klein@charite.de improvement from 5.91 months to 6.24 months in the OS [7] . Up to today, clinical trials with targeted therapies failed to improve OS in PDAC [8] . For example, the humanized monoclonal antibody against vascular endothelial growth factor A (VEGFA), bevacizumab, did not change the overall survival when compared to gemcitabine and erlotinib [9] . Only the FOLFIRINOX regime and Nab-paclitaxel in combination with gemcitabine show an improved response rate (32% and 23%) and a better OS (11 .1 and 8.5 month) compared to gemcitabine monotherapy (response rate 9 and 7% and an OS of 6.8 or 6.7 month, respectively), but at a cost of increased toxicity [10] [11] . Recently, some promising results came from the use of trabedersen, a transforming growth factor-(TGF-) pathway inhibiting substance. Trabedersen is a synthetic 18mer phosphorothioate antisense oligonucleotide that binds specifically to human TGF 2 mRNA and inhibits TGFB2 protein synthesis [12] . In a phase I/II study using this inhibitor, Oettle and colleagues found an OS of 13.4 months in pancreatic cancer patients [13] . The TGF-pathway is one of the core signaling pathways affected in pancreatic cancer and has a major impact on the pathogenesis of PDAC [14] [15] . The importance of TGF-in pancreatic cancer was also confirmed in an elegant gene expression study by Badea et al. in 2008 [16] .
The TGF-superfamily of cytokines consists of more than 30 ligands, namely: TGF-s, activins, inhibins, bone morphogenetic proteins (BMPs), growth and differentiation factors (GDFs), Nodal and antiMüllerian hormone (AMH). The three TGF-isoforms, TGF-1, TGF-2 and TGF-3 were synthesized as a precursor. A homodimer of each form interacts with the latency-associated peptide (LAP) and a latent TGFbinding protein (LTBP) in order to form a larger complex called the large latent complex (LLC). To be activated, the LLC has to be released from the extracellular matrix, which is then followed by a proteolytic cleavage of LAP to release an active TGFisoform to its receptor. TGF-receptor binding leads to the phosphorylation of receptor type I by the constitutively active type II receptor. Receptor type I in turn phosphorylates and activates the receptor-specific SMADs (R-SMADs). By binding SMAD4, the R-SMADs translocate to the nucleus in order to regulate their target genes [reviewed in 12, 17, 18] .
In non-malignant tissue, TGF-is a multifunctional regulator of cell communication, proliferation, apoptosis, differentiation, immune modulation, angiogenesis and extracellular matrix production, and has tumorsuppressor properties. Perturbations of the TGF--pathway during tumorigenesis, promotes migration, invasion and metastasis through epithelial-mesenchymal transition as well as stimulation of extracellular matrix deposition, angiogenesis and escape from immunosurveillance. It is well known that TGF-has tumor-suppressive functions in early tumor stages and tumor-promoting functions in later tumor stages. In this study, we have re-analyzed gene expression data published on PDAC. We determined the 100 topranked genes that were able to discriminate between PDAC and non-malignant pancreatic tissue. About one third of these genes were associated with the TGFpathway, and some of these genes were known to be involved in the cancer switch of TGF-from a tumorsuppressor to a tumor-promoter.
MATERIALS AND METHODS
We reanalyzed 134 recently published gene expression data sets that were produced using the HG-U133 Plus 2.0 microarray platform. The 94 tumor probes comprise 25 PDAC samples from Donahue et al. [19] (GEO [20] For all 134 samples, background correction and normalization was performed, and gene expression level was summarized on probes using the RMA method [23] . A variance shrinkage method was employed [24] and revealed the top 100 differentially expressed genes based on the fdr corrected p-values. All gene expressions were log2-transformed, and the signal intensity changes between tumor and normal samples are expressed as log2-foldchange (logFC). The fdr corrected p-values and the log2-ratio between tumor and normal samples are shown in supplementary file 1.
Both samples and probe sets were unsupervised clustered using euclidean distance and a complete agglomeration function.
Classification was performed using kernlab's implementation of support vector machines [25] using a linear kernel. The models were validated with a performance estimation using a k-fold cross validation (k=3) approach.
For identification of prognostic genes, we used the above-mentioned, two data sets and classified those samples that survived more than 900 days as having good prognosis, and classified all other samples as having bad prognosis. For the identification of prognostic genes, we performed background correction, normalization and gene expression level summarization on probes using the RMA method [23] , followed by a variance shrinkage method [24] that revealed the top differentially expressed genes based on the p-values. The samples were unsupervised clustered using euclidean distance and a complete agglomeration function.
All analyses were performed using the software R [26] associated with packages of the Bioconductor project [27] .
For the generation of Figure 2 , CorrXpression Software was used [28] [29] . Only the 121 top-ranked transcripts were used for the correspondence plot.
Gene annotation was performed with the help of the data bases: PubMed [30] , Entrez Gene [31] , UniProt [32] and iHOP [33] .
For an enrichment analysis, a list of TGF-pathway associated genes published by Ranganathan et al. [34] was further processed. The authors characterized 2.041 genes that are regulated by TGF-(1.757 genes are found exclusively in A549 cells, 733 genes are exclusively regulated in HPL1D cells, and 267 genes are commonly regulated in both cell-lines). The 2.041 genes in this list were further approved to get only those genes with a known HGNC symbol. We used the symbol checker (http://www.genenames.org/cgibin/symbol_checker) and removed all non-approved gene symbols. Furthermore, the synonyms were checked to avoid doubled gene identifiers in the resulting list of TGF-pathway associated genes.
RESULTS
In this study, we have re-analyzed previously published gene expression data from 94 pancreatic Badea et al. 2008 (GSE 15471) and one sample was taken from a healthy pancreas from Roth 2007 (GSE7307). We determined the gene expression profile of genes differentially expressed in PDAC compared to non-malignant pancreatic tissue. Using the 100 top-ranked genes, we were able to discriminate between PDAC and non-malignant pancreatic tissue (Figure 1 ).
Gene Expression Analysis and Classification
Based on the fdr corrected p-value, the best 100 differentially expressed genes (121 probe sets: see supplementary file 1 for detailed information) were selected. The gene wise depiction of the gene expression values for all 100 selected genes is given in supplementary file 2 and is exemplarily shown for fibronectin 1 (FN1) in An unsupervised clustering (Figure 1 ) reveals 6% falsely assigned samples (one tumor and seven normal probes out of 134 samples). 90.3% of all samples were classified correctly as normal or tumor sample using a k-fold (k=3) cross validation.
In order to verify these results, we performed a principal component analysis (PCA) for the top-ranked transcripts with the help of CorrXpression [28] [29] . The PCA was used to examine the relationship between transcripts and experiments. As shown in Figure 2 , the non-malignant and the PDAC samples cluster mainly in two distinct groups. The only healthy pancreatic sample lies in-between the non-malignant samples (not shown). The seven falsely classified samples cluster also into the tumor samples. However, in this analysis, the falsely classified tumor sample is located in the PDAC cluster.
The 121 transcripts corresponding to 100 genes were further annotated with the help of the data bases: PubMed, Entrez Gene, UniProt and iHOP. From the 100 top-ranked genes, 82 genes are known to be involved in cancer pathways. For 68 protein-coding genes a tumor-promoting property was described, of which 23 were already known PDAC cancer genes (red symbols in Table 1 ). For seven genes, tumor-promoting and tumor-suppressor properties were described, and eight further genes have known tumor-suppressor functions ( Table 1 ). ACTN1, ACVR1,  ADAM9, AFAP1, ANO1, ANTXR1, ANXA2, CAPG, CD109, CD47,  COL10A1, COL11A1, COL1A1, COL1A2, COL3A1, COL5A1,  COL5A2, COL6A3, COL8A1, CTHRC1, ECT2, EDNRA, FN1,  GJB2, GPRC5A, HOXB3, INHBA, ITGA2, ITGB5, ITGB6,  KDM5B, KIF26B, KRT19, KRT7, LAMC2, LBH, LTBP1, MAP4,  MAP4K4, MICAL2, MYOF, NOX4, NREP, PLXDC2, PMEPA1,  POSTN, PRKCI, PTGER4, PTGFRN, RAB31, RCN1, RUNX1,  S100P, SLC39A10, SLPI, SOX4, SPARC, STEAP1, SULF1,  TGIF1, THBS2, THY1, TM4SF1, TNFRSF21, TPBG, TRIO,  VCAN, WISP1 4 genes were cancer related: ARHGAP1, HOXA3, MXRA5, ZNF532
8 tumor-suppressor genes: ADAMTS12, ASAP2, DKK3, PHLDA2, PIAS3, RASAL2, STK3, VGLL4 2 tumor-suppressor candidates: MORC2, TTLL5
7 genes with tumor-promoting and tumor-suppressing properties: ACVR1, COL8A1, RUNX1, SULF1, SLPI, TGIF1, THBS2
For 18 genes no involvement in tumorigenesis was found: AHNAK2, ANXA2P2, ATP2C1, CAMSAP2, CEP170, CKLF, CYB5R3, DCBLD1, IDS, ITPRIPL2, KIAA1217, NHS, NTM, PGM2L1, SESTD1, SLC6A6, TMEM87A, LOC283508
The most affected signaling pathways were signal transduction (33 genes), cell adhesion (28 genes), extracellular matrix organization (20 genes), cell migration (20 genes; 5 genes were associated with leucocyte migration), cell apoptosis (18 genes; 8 inhibitors of apoptosis, 9 inducers of apoptosis, and 1 gene where both functions have been described), cell proliferation (17 genes), regulation of transcription (15 genes), and angiogenesis (14 genes). Furthermore, 15 genes were stem cell-associated genes, and 11 genes were known to code for proteins involved in epithelialmesenchymal transition (EMT). For more detailed information, see supplementary files 1 and 3.
TGF-Pathway Associated Genes
Interestingly, 31 out of the selected genes were identified as associated with the TGF-pathway. These genes were described in Table 2 , including their association to tumor progression found in literature. To determine whether the mentioned 31 TFGgenes are randomly selected or significantly enriched in the list of differentially expressed genes, we used a list of approved genes associated with the TGFpathway. Ranganathan et al. published such a list with 2.041 genes [34] . We checked these genes for approved HGNC symbols and for duplications due to synonymous naming using a symbol checker (http://www.genenames.org/cgi-bin/symbol_checker). At the end of this process, we obtained a list of 1.655 genes (see supplementary file 1). Comparing 1.655 TGF-associated genes out of 20.805 human genes (Ensembl [35] version 21.2.14) to 31 TFG-genes within our list of 100 revealed a clear enrichment (3.9-fold) of TFG-genes associated with pancreatic tumor probes.
Prognostic Genes / Survival Analysis
For the prediction of prognostic genes, 69 samples with survival data were taken. We selected two distinct groups: bad prognosis with survival time < 900 days, and good prognosis with survival time > 900 days. The threshold of 900 days was used to obtain two groups of nearly equal size. We performed a differential expression analysis and selected eleven genes that were able to discriminate between patients with good and bad prognoses. The number of genes in the prognosis list was estimated in such a way as to minimize the false-discovery rate. The genes are summarized in Table 3 . The unsupervised clustering of the samples based on the 11 selected genes is shown in Figure 4 . It can be seen that 64 samples (out of 69) were classified correctly (92.8%). 
DISCUSSION
A genetic progression model for pancreatic cancer was recently established [36] . In their model, metastatic PDAC arises from PanIN (pancreatic intraepithelial neoplasia) through multiple genetic and epigenetic events. Early events in tumorigenesis were found to be activating mutations in KRAS in PanIN-1, mutations or epigenetic silencing of CDKN2A in PanIN-2, and inactivating mutations of TP53 and of SMAD4 in PanIN-3. Approximately 55% of pancreatic cancers bear deletions or mutations in SMAD4 [37] [38] . Beside mutations in SMAD4, genetic alterations in genes relevant to the TGF-pathway occur mainly in TGFBR2, BMPR2 and SMAD3. In a study by Jones and colleagues published in 2008, it was shown that 100% of the pancreatic cancers had genetic alterations in the TGF-pathway. Therefore, the TGF-pathway belongs to the core signaling pathways in PDAC [14] . Badea et al. revealed, in a gene expression study that tumor tissues contain a TGF-beta signature as a result, mainly due to the high amounts of stromal cells in tumor samples [16] .
In this work, we have re-analyzed gene expression data from earlier [16] and from more recently published gene expression studies [19, 21] . We were able to determine the 100 top-ranked genes which discriminate best between PDAC and non-malignant pancreatic tissue. Interestingly, about one third of these genes were associated with the TGF-pathway.
Pancreas cancer progression is a cooperate action between tumor cells and stromal cells, namely pancreatic stellate cells (PSC) [39] . The pancreatic tumor cells induce via TGF-, amongst other growth factors, the PSC to build up the extracellular matrix, which itself promotes tumor cell migration, invasion and survival. Thus, we found an overexpression of proteincoding genes like: COL11A1, INHBA and THBS2 that were produced from PSC. These genes were associated with an invasion-associated variant of a desmoplastic reaction and belong to a metastasisassociated gene expression signature [40] . Furthermore, stromal cells of the tumoral pancreas express the reactive oxygen species (ROS)-producing NOX4. It was shown by Barcellos-Hoff and Dix that ROS formation triggers conversion of the latent form of TGF-to its active form, which is one of the most important mechanisms that regulate activation of the TGF-signaling [41] . However, TGF-activation can also be effected by integrins v 5 and v 6 [42] . Integrins 5 and 6 were expressed in pancreatic cancer cell lines (GSE36139 [43] ); for integrin ß6, a strong protein expression in the pancreatic cell lines CAPAN2 and HPAC were shown [44] . These integrins were not normally expressed in epithelial cells and enhance the migratory and invasive behavior of carcinoma cells [42] . Additionally, it was shown that TMEPAI functions in breast cancer cells as a molecular switch that converts TGF-beta from a tumor-suppressor to a tumor-promoter [45] . TMEPAI is also highly expressed in the pancreatic cancer cell lines Panc 04.03, Panc 05.04 and SU.86.86 [43] . In return, TMEAPAI was also found in a stromal signature of esophageal adenocarcinomas and patients overexp- ressing this gene had a significantly poorer outcome [46] . Thus, the activation of the TGF-pathway is also a cooperative effect of PSC and tumor cells.
Since the TGF-pathway is one of the core pathways in PDAC leading to desmoplasia and to highly invasive and metastatic tumor cells, inhibiting this pathway might be a promising therapeutic option. Through this inhibition the extracellular matrix might be reduced, which would lead to a better accessibility for chemotherapeutic drugs.
The earliest data to support the hypothesis of the current study stems from a phase I/II study (NCT00844064) using trabedersen -a complementary sequence to the TGFB2 mRNA. Survival analysis revealed a median overall survival of 13.4 months [13] . A further clinical phase II study applying LY2157299, an orally active transforming growth factor beta receptor kinase inhibitor with or without gemcitabine, is still ongoing (NCT01373164).
The search for a prognostic gene set in pancreatic cancer is still challenging since it is difficult to discriminate pancreatic cancers with a good or bad prognosis. Pancreatic cancer surgery is still a complex operation with morbidity rates of 30% -60% [47] , and most pancreatic cancers were diagnosed in an advanced stage of disease. Further, the median age of onset of PDAC is 71 years [48] , so that many patients suffer from co-morbidity. Another drawback is a lack of freely available clinical data for such a difficult task. In our analysis, we used the survival time of 900 days to select two distinct groups with good and bad prognosis. We performed a differential expression analysis and selected eleven genes that were able to discriminate between patients with a good and bad prognosis. The clustering reveals only a 7.2% misclassification rate. However, these results have to be approved in a larger clinical data set to further evaluate the gene set.
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